Targeting nail psoriasis: IL-17A inhibitors demonstrate site-specific superiority over IL-23 inhibitor in a 24-week dermoscopy-guided real-world cohort
IL-17A inhibitors and the IL-23 inhibitor demonstrated significant efficacy in improving both nail and skin lesions in psoriasis. Notably, IL-17A inhibitors exhibited superior overall efficacy compared to IL-23 inhibitor. Specifically, SEC excelled in improving dermoscopic nail matrix changes, whereas IXE was more potent for nail bed pathology. All groups significantly improved patients' life quality and exhibited good safety profiles.
Authors
- Yan Xia (ORCID: https://orcid.org/0000-0002-2203-467X)
- Huiwei Wang
- Minglan Shi (ORCID: https://orcid.org/0000-0003-4307-4125)
- Jialiang Shi (ORCID: https://orcid.org/0009-0004-9340-0720)
- Yaqian Cui
- Bin Wang (ORCID: https://orcid.org/0000-0003-1606-5004)
- Zeng Li-hua (ORCID: https://orcid.org/0000-0003-3187-9911)
- Suchun Hou
Institutions
- Shenzhen University (CN)
- Shenzhen Maternity and Child Healthcare Hospital (CN)
- ShenZhen People’s Hospital (CN)
- University of Hong Kong - Shenzhen Hospital (CN)
- University of Hong Kong (HK)
Publication Details
- Journal
- Frontiers in Immunology
- Published
- 2025-04-08
- DOI
- https://doi.org/10.3389/fimmu.2025.1573715
- Citations
- 2
- Primary Topic
- Psoriasis: Treatment and Pathogenesis
- Type
- article
- Field-Weighted Citation Impact
- 1.59